Pacific Edge Launches NZ$6 Million Retail Offer to Back Medicare Re-Coverage

Retail Offer Opens After Oversubscribed Placement

Pacific Edge Limited (NZX/ASX:PEB) has kicked off a NZ$6 million retail share offer priced at NZ$0.17 per share, inviting eligible New Zealand shareholders to participate following a NZ$25.4 million placement to institutional investors at the same price. This move aims to bolster the company’s finances as it pushes to regain Medicare reimbursement for its bladder cancer diagnostic tests in the US.

The retail offer opens on 14 May 2026 and closes on 28 May 2026, allowing shareholders on the register as of 8 May 2026 with a New Zealand address to apply for up to NZ$50,000 of shares each. Pacific Edge retains discretion to accept oversubscriptions beyond the NZ$6 million target, with potential scaling back of applications based on existing shareholdings.

Medicare Re-Coverage Hinge for Growth Prospects

Central to the capital raise is the company’s expectation that Novitas, the Medicare administrative contractor for Pacific Edge’s US laboratory, will release a draft Local Coverage Determination (LCD) for hematuria evaluation by September 2026. This draft is anticipated to include coverage for Pacific Edge’s Cxbladder Triage and possibly Triage Plus urine-based biomarker tests, which have been supported by peer-reviewed publications and recognized in clinical guidelines.

A successful Medicare coverage policy would distinguish hematuria patients eligible for Cxbladder testing from cancer patients currently excluded under the non-coverage LCD effective since April 2025. Pacific Edge plans to engage with Novitas for claim-by-claim reimbursement upon draft release, which could significantly improve revenue and help reduce the company’s monthly cash burn, currently targeted at NZ$2.5 million for FY27, down from NZ$2.85 million in FY26.

Capital Raise to Support Operations and Innovation

Chairman Simon Flood emphasised that the capital raising initiative aims to strengthen Pacific Edge’s balance sheet to support ongoing operations, accelerate evidence generation, and continue product development and innovation. The company is determined to maintain momentum in expanding adoption of its bladder cancer diagnostics, particularly in the US and Asia Pacific markets.

All directors intend to participate in the retail offer, aligning their interests with shareholders. The shares issued under the offer will rank equally with existing ordinary shares and will be quoted on the NZX Main Board and ASX.

The retail offer is not underwritten, and applications will be irrevocable once submitted. Shareholders are encouraged to apply online or via a hard copy application form with payment by direct debit in New Zealand dollars. Pacific Edge reserves the right to withdraw or amend the offer at its discretion.

Shareholder Impact and Dilution Risk

Shareholders who do not participate in the offer risk dilution of their ownership stake, estimated at approximately 15.3% if the full NZ$31.4 million (placement plus retail offer) is raised. The offer is structured to provide equal pricing to retail shareholders as institutional investors, but it is not a pro-rata offer, meaning shareholding percentages may shift depending on individual participation and scaling outcomes.

Pacific Edge’s recent capital raising activities, including the NZ$25.4 million placement, have been met with strong investor support, reflecting confidence in the company’s strategic direction despite ongoing uncertainty around Medicare coverage. The company’s efforts to regain coverage are a critical catalyst for unlocking broader commercial payer reimbursement and revenue growth opportunities.

This retail offer follows the company’s earlier capital raise announcement and is part of a broader strategy to stabilize finances and fund growth initiatives amid a challenging reimbursement landscape. The market will be watching closely as the Medicare draft LCD approaches, which could mark a turning point for Pacific Edge’s US market prospects.

Investors should note the timing and finalisation of the Medicare LCD remain uncertain, and the offer’s success depends on both shareholder uptake and regulatory developments. The company’s focus on clinical evidence generation and product innovation continues alongside these reimbursement efforts, aiming to solidify its position in the bladder cancer diagnostics sector.

Pacific Edge’s capital raising journey, including the recent NZ$25.4 million placement, is detailed in the company’s NZ$25.4 million placement announcement, while the broader strategic context of its Medicare coverage challenges was outlined in the Medicare coverage remains in limbo report.